Arulananda, Surein
O’Brien, Megan
Evangelista, Marco
Harris, Tiffany J.
Steinohrt, Nikita S. http://orcid.org/0000-0002-2672-6331
Jenkins, Laura J.
Walkiewicz, Marzena
O’Donoghue, Robert J. J.
Poh, Ashleigh R.
Thapa, Bibhusal
Williams, David S.
Leong, Trishe
Mariadason, John M. http://orcid.org/0000-0001-9123-7684
Li, Xia
Cebon, Jonathan
Lee, Erinna F.
John, Thomas
Fairlie, W. D. http://orcid.org/0000-0002-2498-1160
Funding for this research was provided by:
La Trobe University
Lung Foundation Australia
Department of Health | National Health and Medical Research Council (GNT1166447, GNT1157551)
Department of Education and Training | Australian Research Council (FT150100212)
Victorian Cancer Agency (MCRF19045)
Article History
Received: 23 August 2020
Accepted: 20 September 2020
First Online: 31 October 2020
Change Date: 15 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41420-020-00388-7
Conflict of interest
: W.D.F. and E.F.L. were previously employees of The Walter and Eliza Hall Institute where they were involved in collaborations with AbbVie and Genentech to develop and characterise BH3-mimetic drugs and receive payments in respect of Venetoclax. They have an on-going collaboration with Astra Zeneca studying BH3-mimetics. S.A. has received speaker fees and travel support from Merck-Sharpe Dohme, Astra Zeneca, Boehringer-Ingelheim, Bristol-Myers Squibb and Roche, outside the submitted work. J.C. has received speaker fees and travel support from Amgen, Bristol-Myers Squibb, GlaxoSmith Kline, Merck; Merck Sharp & Dohme and Novartis, outside the submitted work. T.J. has received speaker fees and travel support from Pfizer, Astra Zeneca, BMS, Novartis, Merck Sharp & Dohme, Boehringer-Ingelheim, Takeda, Merck and Roche, outside the submitted work.